Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting
Clinical Outcome Assessment Tools Detected and Quantified Baseline Abnormalities Clinically Relevant Improvement Seen in Multiple Neuromotor Tests Company to Host Clinical Update Conference Call Today at 8:30 a.m. ET AUSTIN, Texas , April 12, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting
AUSTIN, Texas , April 05, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will present Phase 1 dose
Toggle Summary Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting
Company to Host Clinical Update Conference Call on April 12 at 8:30 a.m. ET AUSTIN, Texas , April 03, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare
Toggle Summary Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials
Topline Safety and Clinical Activity Phase 1 Data Expected in 4Q 2018 AUSTIN, Texas , April 02, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics Appoints Dr. Ivana Magovčević-Liebisch to Board of Directors
AUSTIN, Texas , March 26, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Ivana
Toggle Summary Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference
Company to Webcast Presentation on Tuesday, March 27 at 9:00 a.m. ET AUSTIN, Texas , March 20, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results
Repeat Doses of Company’s Pegzilarginase Produces Marked and Sustained Reductions in Plasma Arginine Levels      Accompanying Reductions in Other Related Guanidino Compounds Also Seen  Additional Arginase 1 Deficiency Clinical Data in April at 2018 ACMG Annual Clinical Genetics Meeting Clinical and
Toggle Summary Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase
Topline Safety and Clinical Activity Data Expected in 4Q 2018 AUSTIN, Texas , March 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases
Toggle Summary Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders
Company to Hold Clinical and Corporate Update Conference Call at 8:00 a.m. ET on Tuesday, March 13 AUSTIN, Texas , March 06, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for
Toggle Summary Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference
AUSTIN, Texas , Jan. 18, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will present a poster
Toggle Summary Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
Company to Webcast Presentation on Thursday, December 14 at 8:30 a.m. ET AUSTIN, Texas , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with rare
Toggle Summary Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)
Clinical Agreement Reached with FDA to Enable Pediatric Dosing AUSTIN, Texas , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
AUSTIN, Texas , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today provided a corporate update and reported
Toggle Summary Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting
AUSTIN, Texas , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will deliver a poster
Toggle Summary Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer
AUSTIN, Texas , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced it has entered into a clinical